RxDoctor Payments Data

Jonathan Luker

Family · Scottdale, PANPI 1992071732

Payments from drug & device makers

$1,911in general payments, 2019–2025

Across 102 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$405
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$320
  • Amgen$195
  • Teva Pharmaceuticals USA, Inc.$191
  • Novo Nordisk$165
  • GSK$148
  • plus $487 from 10 others

What the payments were for

  • Food & beverage$1,911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,911 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,512
Medicare patients
27
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$47,268
RybelsusSemaglutide33$34,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$33,131
MounjaroTirzepatide28$31,634
EliquisApixaban34$28,937
TrulicityDulaglutide27$27,822
XareltoRivaroxaban34$22,563
TradjentaLinagliptin18$12,515
Breo ElliptaFluticasone/Vilanterol22$8,594
MovantikNaloxegol Oxalate15$6,373
Methylphenidate ErMethylphenidate Hcl16$4,294
Ezetimibe78$2,936
PremarinEstrogens, Conjugated13$2,807
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$2,340
Pantoprazole Sodium178$2,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$405$60,02369 claims
Boehringer IngelheimJardiance, Tradjenta$93$59,78377 claims
GSKTrelegy Ellipta, Breo Ellipta$148$41,72570 claims
Novo NordiskRybelsus$165$34,46733 claims
PfizerEliquis, Premarin$44$31,74447 claims
Johnson & JohnsonXarelto$15$22,56334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Scottdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →